机构地区:[1]河南省肿瘤医院泌尿外科,河南郑州450008
出 处:《现代肿瘤医学》2020年第9期1489-1492,共4页Journal of Modern Oncology
基 金:2018年度河南省医学科技攻关计划项目(编号:2018020506)。
摘 要:目的:检测长链非编码RNA FAL1(long non-coding RNA FAL1,lncRNA FAL1)在前列腺癌(PCa)患者癌组织(Tum)和相邻非癌变组织(Non-tum)中的表达差异及其与预后的关系。方法:回顾性选取我院2015年4月至2017年5月治疗的89例PCa患者作为研究对象,记录患者初诊时的年龄、病理Gleason评分、血清中前列腺特异性抗原(prostate specific antigen,PSA)以及TNM分期等。qRT-PCR检测癌组织或相邻非癌变组织中lncRNA FAL1相对表达水平,根据lncRNA FAL1表达水平的中位值将PCa癌组织组分为低、高表达组,通过Log-Rank检验和Kaplan-Meier生存曲线分析lncRNA FAL1对PCa患者预后的影响。最后,Cox多因素分析评估lncRNA FAL1表达与PCa患者临床病理特征和预后的关系。结果:与Non-tum组织相比,Tum组织中lncRNA FAL1的表达水平显著性升高,P<0.01;另外,lncRNA FAL1在组织中的表达水平与PCa患者Gleason评分分级、T分期、淋巴转移及远处转移显著相关,P<0.05;和年龄及PSA等指标无关。lncRNA FAL1高表达组的总体生存时间和无进展生存期均显著降低(P<0.05);lncRNA FAL1高表达是PCa患者预后的危险因素(RR=1.961,95%CI:0.635~2.107,P=0.012)。结论:lncRNA FAL1在PCa患者癌组织中高表达,是预测PCa预后的危险因素,有望成为PCa治疗新的诊断生物标志物和治疗靶点。Objective:To investigate the expression differences of long non-coding RNA FAL1(lncRNA FAL1)in cancer tissues(Tum)and adjacent non-cancerous tissues(Non-tum)in patients with prostate cancer(PCa)and its relationship with prognosis.Methods:89 patients with PCa treated in our hospital from April 2015 to May 2017 were retrospectively selected as the study subjects.The initial diagnosis age,serum prostate specific antigen(PSA),pathological Gleason score,TNM stage and survival status of patients were recorded.The relative expression level of lncRNA FAL1 in cancer tissues or adjacent non-cancerous tissues was detected by qRT-PCR.According to the median expression level of lncRNA FAL1,PCa cancer tissues were divided into low and high expression groups.The prognostic effects of lncRNA FAL1 on PCa patients were analyzed by Log-Rank test and Kaplan-Meier survival curve.Cox multivariate analysis was used to evaluate the relationship between the expression of lncRNA FAL1 and clinicopathological characteristics and prognosis of PCa patients.Results:Compared with non-cancerous tissues,the expression level of lncRNA FAL1 in cancer tissues increased significantly(P<0.01).The expression level of lncRNA FAL1 was not correlated with age and serum PSA level of patients,but was significantly correlated with Gleason score,clinical stage,lymphatic metastasis and distant metastasis(P<0.05).Compared with the high expression group of lncRNA FAL1,the overall survival(OS)and progressive free survival(PFS)of the low expression group were significantly higher(P<0.05).High expression of lncRNA FAL1 was a risk factor for prognosis in PCa patients(RR=1.961,95%CI:0.635~2.107,P=0.012).Conclusion:The high expression of lncRNA FAL1 in cancer tissues of PCa patients is a risk factor for predicting the prognosis of PCa,and it is expected to become a new diagnostic biomarker and therapeutic target for PCa treatment.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...